<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://ssistrategy.com/wp-content/plugins/seriously-simple-podcasting/templates/feed-stylesheet.xsl?v=2"?><rss version="2.0"
	 xmlns:content="http://purl.org/rss/1.0/modules/content/"
	 xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	 xmlns:dc="http://purl.org/dc/elements/1.1/"
	 xmlns:atom="http://www.w3.org/2005/Atom"
	 xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	 xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	 xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd"
	 xmlns:googleplay="http://www.google.com/schemas/play-podcasts/1.0"
	 xmlns:podcast="https://podcastindex.org/namespace/1.0"
	 xmlns:ssp="https://castos.com/seriously-simple-podcasting/namespace/1.0"
	>
		<channel>
		<title>The Emerging Biotech Leader</title>
		<atom:link href="https://ssistrategy.com/feed/podcast/ssi-strategy/" rel="self" type="application/rss+xml"/>
		<link>https://ssistrategy.com/podcasts/ssi-strategy/</link>
		<description>Biotech—it&#039;s complicated.

A successful product launch requires grit, determination, and clear direction.

But let’s be real, the path to launch isn’t a straight one.

There are curves, hard turns, and dead ends.

Here’s the good news, you don’t have to navigate the complexities alone.

Welcome to The Emerging Biotech Leader, where we help biotech leaders maximize the value of their therapeutics from clinical development to product launch.</description>
		<lastBuildDate>Tue, 29 Sep 2026 14:55:52 +0000</lastBuildDate>
		<language>en</language>
		<copyright>© 2024 SSI Strategy</copyright>
		<itunes:subtitle>Biotech—it&#039;s complicated.</itunes:subtitle>
		<itunes:author>SSI Strategy</itunes:author>
		<itunes:type>episodic</itunes:type>
		<itunes:summary>Biotech—it&#039;s complicated.

A successful product launch requires grit, determination, and clear direction.

But let’s be real, the path to launch isn’t a straight one.

There are curves, hard turns, and dead ends.

Here’s the good news, you don’t have to navigate the complexities alone.

Welcome to The Emerging Biotech Leader, where we help biotech leaders maximize the value of their therapeutics from clinical development to product launch.</itunes:summary>
		<itunes:owner>
			<itunes:name>SSI Strategy</itunes:name>
		</itunes:owner>
		<itunes:explicit>false</itunes:explicit>
		<itunes:image href="https://ssistrategy.com/wp-content/uploads/2024/06/mdhmni5wbmc-scaled.jpg"></itunes:image>
			<image>
				<url>https://ssistrategy.com/wp-content/uploads/2024/06/mdhmni5wbmc-scaled.jpg</url>
				<title>The Emerging Biotech Leader</title>
				<link>https://ssistrategy.com/podcasts/ssi-strategy/</link>
			</image>
		<itunes:category text="Business">
		</itunes:category>
		<itunes:category text="Science">
									<itunes:category text="Life Sciences"></itunes:category>
							</itunes:category>
		<googleplay:author><![CDATA[SSI Strategy]]></googleplay:author>
						<googleplay:description>Biotech—it&#039;s complicated.

A successful product launch requires grit, determination, and clear direction.

But let’s be real, the path to launch isn’t a straight one.

There are curves, hard turns, and dead ends.

Here’s the good news, you don’t have to navigate the complexities alone.

Welcome to The Emerging Biotech Leader, where we help biotech leaders maximize the value of their therapeutics from clinical development to product launch.</googleplay:description>
			<googleplay:explicit>No</googleplay:explicit>
			<googleplay:image href="https://ssistrategy.com/wp-content/uploads/2024/06/mdhmni5wbmc-scaled.jpg"></googleplay:image>
			<podcast:locked>yes</podcast:locked>
		<podcast:guid>73c0b0af-8570-513b-a42d-1711ab123215</podcast:guid>
		
		<!-- podcast_generator="SSP by Castos/3.17.0" Seriously Simple Podcasting plugin for WordPress (https://wordpress.org/plugins/seriously-simple-podcasting/) -->
		<generator>https://wordpress.org/?v=7.1.3</generator>

<item>
	<title>From Academia to Biotech: Making the Transition into Biotech Leadership</title>
	<link>https://ssistrategy.com/podcast/from-academia-to-biotech-making-the-transition-into-biotech-leadership/</link>
	<pubDate>Thu, 10 Sep 2026 13:20:05 +0000</pubDate>
	<dc:creator><![CDATA[SSI Strategy]]></dc:creator>
	<guid isPermaLink="false">a5b556be-9bbf-5c65-9f0d-282571f4faa2</guid>
	<description><![CDATA[Mattia Calissano, VP Medical at SSI Strategy, discusses moving from academic research into drug development, communicating scientific evidence to investors, and adapting to the commercial realities of biotech. ]]></description>
	<itunes:subtitle><![CDATA[Mattia Calissano, VP Medical at SSI Strategy, discusses moving from academic research into drug development, communicating scientific evidence to investors, and adapting to the commercial realities of biotech. ]]></itunes:subtitle>
	<content:encoded><![CDATA[Mattia Calissano, VP Medical at SSI Strategy, discusses moving from academic research into drug development, communicating scientific evidence to investors, and adapting to the commercial realities of biotech. ]]></content:encoded>
	<enclosure url="https://media.transistor.fm/d807c737/948a1e9b.mp3" length="28848058" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Mattia Calissano, VP Medical at SSI Strategy, discusses moving from academic research into drug development, communicating scientific evidence to investors, and adapting to the commercial realities of biotech. ]]></itunes:summary>
	<itunes:image href="https://ssistrategy.com/wp-content/uploads/2026/09/from-academia-to-biotech-leadership.jpg"></itunes:image>
	<ssp:image>
		<ssp:url>https://ssistrategy.com/wp-content/uploads/2026/09/from-academia-to-biotech-leadership.jpg</ssp:url>
		<ssp:title>From Academia to Biotech: Making the Transition into Biotech Leadership</ssp:title>
	</ssp:image>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>00:29:57</itunes:duration>
	<itunes:author><![CDATA[SSI Strategy]]></itunes:author>	<googleplay:description><![CDATA[Mattia Calissano, VP Medical at SSI Strategy, discusses moving from academic research into drug development, communicating scientific evidence to investors, and adapting to the commercial realities of biotech. ]]></googleplay:description>
	<googleplay:image href="https://ssistrategy.com/wp-content/uploads/2026/09/from-academia-to-biotech-leadership.jpg"></googleplay:image>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>When the Science Becomes a Company</title>
	<link>https://ssistrategy.com/podcast/when-the-science-becomes-a-company/</link>
	<pubDate>Thu, 20 Aug 2026 14:10:07 +0000</pubDate>
	<dc:creator><![CDATA[SSI Strategy]]></dc:creator>
	<guid isPermaLink="false">4b955e19-ddac-57c2-8c6d-00c8fbbaac4c</guid>
	<description><![CDATA[Samir Ounzain, Scientific Co-Founder and CEO of HAYA Therapeutics, looks at how the founder's role changes as the science becomes a company and the team grows around it. ]]></description>
	<itunes:subtitle><![CDATA[Samir Ounzain, Scientific Co-Founder and CEO of HAYA Therapeutics, looks at how the founders role changes as the science becomes a company and the team grows around it. ]]></itunes:subtitle>
	<content:encoded><![CDATA[Samir Ounzain, Scientific Co-Founder and CEO of HAYA Therapeutics, looks at how the founder's role changes as the science becomes a company and the team grows around it. ]]></content:encoded>
	<enclosure url="https://media.transistor.fm/9e23e7e8/40e9c565.mp3" length="33723975" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Samir Ounzain, Scientific Co-Founder and CEO of HAYA Therapeutics, looks at how the founder's role changes as the science becomes a company and the team grows around it. ]]></itunes:summary>
	<itunes:image href="https://ssistrategy.com/wp-content/uploads/2026/08/when-the-science-becomes-a-company.jpg"></itunes:image>
	<ssp:image>
		<ssp:url>https://ssistrategy.com/wp-content/uploads/2026/08/when-the-science-becomes-a-company.jpg</ssp:url>
		<ssp:title>When the Science Becomes a Company</ssp:title>
	</ssp:image>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>00:35:04</itunes:duration>
	<itunes:author><![CDATA[SSI Strategy]]></itunes:author>	<googleplay:description><![CDATA[Samir Ounzain, Scientific Co-Founder and CEO of HAYA Therapeutics, looks at how the founder's role changes as the science becomes a company and the team grows around it. ]]></googleplay:description>
	<googleplay:image href="https://ssistrategy.com/wp-content/uploads/2026/08/when-the-science-becomes-a-company.jpg"></googleplay:image>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Flexible Leadership in Biotech: Building Teams Around Program Needs</title>
	<link>https://ssistrategy.com/podcast/flexible-leadership-in-biotech-building-teams-around-program-needs/</link>
	<pubDate>Thu, 09 Jul 2026 12:14:12 +0000</pubDate>
	<dc:creator><![CDATA[SSI Strategy]]></dc:creator>
	<guid isPermaLink="false">9865ae61-114c-5b43-bce8-0ea43667deea</guid>
	<description><![CDATA[Chris Kennedy, CEO of Pacific Genetech, examines a different approach to building leadership teams in early-stage biotech: building organizations around program needs rather than fixed leadership structures. ]]></description>
	<itunes:subtitle><![CDATA[Chris Kennedy, CEO of Pacific Genetech, examines a different approach to building leadership teams in early-stage biotech: building organizations around program needs rather than fixed leadership structures. ]]></itunes:subtitle>
	<content:encoded><![CDATA[Chris Kennedy, CEO of Pacific Genetech, examines a different approach to building leadership teams in early-stage biotech: building organizations around program needs rather than fixed leadership structures. ]]></content:encoded>
	<enclosure url="https://media.transistor.fm/61cce1b0/6ebea1d4.mp3" length="30275929" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Chris Kennedy, CEO of Pacific Genetech, examines a different approach to building leadership teams in early-stage biotech: building organizations around program needs rather than fixed leadership structures. ]]></itunes:summary>
	<itunes:image href="https://ssistrategy.com/wp-content/uploads/2026/07/flexible-leadership-in-biotech-building-teams-around-program-needs-.jpg"></itunes:image>
	<ssp:image>
		<ssp:url>https://ssistrategy.com/wp-content/uploads/2026/07/flexible-leadership-in-biotech-building-teams-around-program-needs-.jpg</ssp:url>
		<ssp:title>Flexible Leadership in Biotech: Building Teams Around Program Needs</ssp:title>
	</ssp:image>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>00:31:26</itunes:duration>
	<itunes:author><![CDATA[SSI Strategy]]></itunes:author>	<googleplay:description><![CDATA[Chris Kennedy, CEO of Pacific Genetech, examines a different approach to building leadership teams in early-stage biotech: building organizations around program needs rather than fixed leadership structures. ]]></googleplay:description>
	<googleplay:image href="https://ssistrategy.com/wp-content/uploads/2026/07/flexible-leadership-in-biotech-building-teams-around-program-needs-.jpg"></googleplay:image>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Designing Studies that Work in Complex Settings</title>
	<link>https://ssistrategy.com/podcast/designing-studies-that-work-in-complex-settings/</link>
	<pubDate>Fri, 22 May 2026 11:48:10 +0000</pubDate>
	<dc:creator><![CDATA[SSI Strategy]]></dc:creator>
	<guid isPermaLink="false">a6523142-ac2a-5e84-88b1-12f3c0b28a7f</guid>
	<description><![CDATA[Brendan Slagle, Senior Director, Medical at SSI Strategy discusses why operational feasibility needs to be built into study design from the beginning rather than addressed later during execution. ]]></description>
	<itunes:subtitle><![CDATA[Brendan Slagle, Senior Director, Medical at SSI Strategy discusses why operational feasibility needs to be built into study design from the beginning rather than addressed later during execution. ]]></itunes:subtitle>
	<content:encoded><![CDATA[Brendan Slagle, Senior Director, Medical at SSI Strategy discusses why operational feasibility needs to be built into study design from the beginning rather than addressed later during execution. ]]></content:encoded>
	<enclosure url="https://media.transistor.fm/c4551bf1/91287719.mp3" length="18286983" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Brendan Slagle, Senior Director, Medical at SSI Strategy discusses why operational feasibility needs to be built into study design from the beginning rather than addressed later during execution. ]]></itunes:summary>
	<itunes:image href="https://ssistrategy.com/wp-content/uploads/2026/05/designing-studies-that-work-in-complex-settings.jpg"></itunes:image>
	<ssp:image>
		<ssp:url>https://ssistrategy.com/wp-content/uploads/2026/05/designing-studies-that-work-in-complex-settings.jpg</ssp:url>
		<ssp:title>Designing Studies that Work in Complex Settings</ssp:title>
	</ssp:image>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>00:18:55</itunes:duration>
	<itunes:author><![CDATA[SSI Strategy]]></itunes:author>	<googleplay:description><![CDATA[Brendan Slagle, Senior Director, Medical at SSI Strategy discusses why operational feasibility needs to be built into study design from the beginning rather than addressed later during execution. ]]></googleplay:description>
	<googleplay:image href="https://ssistrategy.com/wp-content/uploads/2026/05/designing-studies-that-work-in-complex-settings.jpg"></googleplay:image>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Rethinking Trial Design for Rare Diseases</title>
	<link>https://ssistrategy.com/podcast/rethinking-trial-design-for-rare-diseases/</link>
	<pubDate>Fri, 08 May 2026 13:34:45 +0000</pubDate>
	<dc:creator><![CDATA[SSI Strategy]]></dc:creator>
	<guid isPermaLink="false">b8102577-3a55-53f2-b376-bd39ad954374</guid>
	<description><![CDATA[Marshall Summar, CEO & Founder of Uncommon Cures, discusses why many conventional trial models break down in rare disease settings, and what stronger alternatives look like in practice.]]></description>
	<itunes:subtitle><![CDATA[Marshall Summar, CEO & Founder of Uncommon Cures, discusses why many conventional trial models break down in rare disease settings, and what stronger alternatives look like in practice.]]></itunes:subtitle>
	<content:encoded><![CDATA[Marshall Summar, CEO & Founder of Uncommon Cures, discusses why many conventional trial models break down in rare disease settings, and what stronger alternatives look like in practice.]]></content:encoded>
	<enclosure url="https://media.transistor.fm/80b2bd41/58d0f20c.mp3" length="35299650" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Marshall Summar, CEO & Founder of Uncommon Cures, discusses why many conventional trial models break down in rare disease settings, and what stronger alternatives look like in practice.]]></itunes:summary>
	<itunes:image href="https://ssistrategy.com/wp-content/uploads/2026/05/rethinking-trial-design-for-rare-diseases.jpg"></itunes:image>
	<ssp:image>
		<ssp:url>https://ssistrategy.com/wp-content/uploads/2026/05/rethinking-trial-design-for-rare-diseases.jpg</ssp:url>
		<ssp:title>Rethinking Trial Design for Rare Diseases</ssp:title>
	</ssp:image>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>00:36:39</itunes:duration>
	<itunes:author><![CDATA[SSI Strategy]]></itunes:author>	<googleplay:description><![CDATA[Marshall Summar, CEO & Founder of Uncommon Cures, discusses why many conventional trial models break down in rare disease settings, and what stronger alternatives look like in practice.]]></googleplay:description>
	<googleplay:image href="https://ssistrategy.com/wp-content/uploads/2026/05/rethinking-trial-design-for-rare-diseases.jpg"></googleplay:image>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Driving Global Patient Access: Managed Access as a Strategic Lever</title>
	<link>https://ssistrategy.com/podcast/managed-access-global-patient-access-biotech/</link>
	<pubDate>Thu, 05 Feb 2026 12:45:12 +0000</pubDate>
	<dc:creator><![CDATA[SSI Strategy]]></dc:creator>
	<guid isPermaLink="false">8cca1344-57af-5c76-8d04-f4c92b555d3d</guid>
	<description><![CDATA[Nicky Wisener explores how emerging biotechs can think more strategically about patient access well before commercialization. ]]></description>
	<itunes:subtitle><![CDATA[Nicky Wisener explores how emerging biotechs can think more strategically about patient access well before commercialization. ]]></itunes:subtitle>
	<content:encoded><![CDATA[Nicky Wisener explores how emerging biotechs can think more strategically about patient access well before commercialization. ]]></content:encoded>
	<enclosure url="https://media.transistor.fm/d340a09c/e43d1015.mp3" length="21519859" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Nicky Wisener explores how emerging biotechs can think more strategically about patient access well before commercialization. ]]></itunes:summary>
	<itunes:image href="https://ssistrategy.com/wp-content/uploads/2026/02/ep-58-podcast-featured-image.jpg"></itunes:image>
	<ssp:image>
		<ssp:url>https://ssistrategy.com/wp-content/uploads/2026/02/ep-58-podcast-featured-image.jpg</ssp:url>
		<ssp:title>Driving Global Patient Access: Managed Access as a Strategic Lever</ssp:title>
	</ssp:image>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>00:22:17</itunes:duration>
	<itunes:author><![CDATA[SSI Strategy]]></itunes:author>	<googleplay:description><![CDATA[Nicky Wisener explores how emerging biotechs can think more strategically about patient access well before commercialization. ]]></googleplay:description>
	<googleplay:image href="https://ssistrategy.com/wp-content/uploads/2026/02/ep-58-podcast-featured-image.jpg"></googleplay:image>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Rare Disease Commercialization: Beyond Approval</title>
	<link>https://ssistrategy.com/podcast/rare-disease-commercialization/</link>
	<pubDate>Wed, 14 Jan 2026 15:53:16 +0000</pubDate>
	<dc:creator><![CDATA[SSI Strategy]]></dc:creator>
	<guid isPermaLink="false">d1868dcb-daa3-5881-8c08-780a689a763e</guid>
	<description><![CDATA[Matt Trudeau discusses what it means to operate within a family-run pharmaceutical company and how that model shapes decision-making differently than a public or venture-backed organization.  ]]></description>
	<itunes:subtitle><![CDATA[Matt Trudeau discusses what it means to operate within a family-run pharmaceutical company and how that model shapes decision-making differently than a public or venture-backed organization.  ]]></itunes:subtitle>
	<content:encoded><![CDATA[Matt Trudeau discusses what it means to operate within a family-run pharmaceutical company and how that model shapes decision-making differently than a public or venture-backed organization.  ]]></content:encoded>
	<enclosure url="https://media.transistor.fm/8f0ed7bd/05fabb10.mp3" length="30786221" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Matt Trudeau discusses what it means to operate within a family-run pharmaceutical company and how that model shapes decision-making differently than a public or venture-backed organization.  ]]></itunes:summary>
	<itunes:image href="https://ssistrategy.com/wp-content/uploads/2026/01/rare-disease-commercialization.jpg"></itunes:image>
	<ssp:image>
		<ssp:url>https://ssistrategy.com/wp-content/uploads/2026/01/rare-disease-commercialization.jpg</ssp:url>
		<ssp:title>Rare Disease Commercialization: Beyond Approval</ssp:title>
	</ssp:image>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>00:31:55</itunes:duration>
	<itunes:author><![CDATA[SSI Strategy]]></itunes:author>	<googleplay:description><![CDATA[Matt Trudeau discusses what it means to operate within a family-run pharmaceutical company and how that model shapes decision-making differently than a public or venture-backed organization.  ]]></googleplay:description>
	<googleplay:image href="https://ssistrategy.com/wp-content/uploads/2026/01/rare-disease-commercialization.jpg"></googleplay:image>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Clinical Operations as a Strategic Function</title>
	<link>https://ssistrategy.com/podcast/clinical-operations-as-a-strategic-function/</link>
	<pubDate>Fri, 05 Dec 2025 08:20:42 +0000</pubDate>
	<dc:creator><![CDATA[SSI Strategy]]></dc:creator>
	<guid isPermaLink="false">f35e3fc4-53a0-5927-863f-ea494281d101</guid>
	<description><![CDATA[Meaghan Powers, Senior Director of Clinical Operations at SSI Strategy, offers a clear view of where clinical operations drives strategic value and how early engagement can set emerging biotechs up for success.]]></description>
	<itunes:subtitle><![CDATA[Meaghan Powers, Senior Director of Clinical Operations at SSI Strategy, offers a clear view of where clinical operations drives strategic value and how early engagement can set emerging biotechs up for success.]]></itunes:subtitle>
	<content:encoded><![CDATA[Meaghan Powers, Senior Director of Clinical Operations at SSI Strategy, offers a clear view of where clinical operations drives strategic value and how early engagement can set emerging biotechs up for success.]]></content:encoded>
	<enclosure url="https://media.transistor.fm/79b2bd06/0ac19eda.mp3" length="20265713" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Meaghan Powers, Senior Director of Clinical Operations at SSI Strategy, offers a clear view of where clinical operations drives strategic value and how early engagement can set emerging biotechs up for success.]]></itunes:summary>
	<itunes:image href="https://ssistrategy.com/wp-content/uploads/2025/12/ep-56-podcast-featured-image.jpg"></itunes:image>
	<ssp:image>
		<ssp:url>https://ssistrategy.com/wp-content/uploads/2025/12/ep-56-podcast-featured-image.jpg</ssp:url>
		<ssp:title>Clinical Operations as a Strategic Function</ssp:title>
	</ssp:image>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>00:20:59</itunes:duration>
	<itunes:author><![CDATA[SSI Strategy]]></itunes:author>	<googleplay:description><![CDATA[Meaghan Powers, Senior Director of Clinical Operations at SSI Strategy, offers a clear view of where clinical operations drives strategic value and how early engagement can set emerging biotechs up for success.]]></googleplay:description>
	<googleplay:image href="https://ssistrategy.com/wp-content/uploads/2025/12/ep-56-podcast-featured-image.jpg"></googleplay:image>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>How Clinical Operations Shapes Biotech Strategy</title>
	<link>https://ssistrategy.com/podcast/how-clinical-operations-shapes-biotech-strategy/</link>
	<pubDate>Fri, 21 Nov 2025 10:19:55 +0000</pubDate>
	<dc:creator><![CDATA[SSI Strategy]]></dc:creator>
	<guid isPermaLink="false">13141d1f-77ac-5a0a-97bf-4a4cb1f5d2c5</guid>
	<description><![CDATA[Sharon Arnold, a seasoned clinical operations executive with more than two decades of experience in both large pharma and emerging biotechs, speaks about how operational leadership determines whether innovation reaches the clinic successfully. ]]></description>
	<itunes:subtitle><![CDATA[Sharon Arnold, a seasoned clinical operations executive with more than two decades of experience in both large pharma and emerging biotechs, speaks about how operational leadership determines whether innovation reaches the clinic successfully. ]]></itunes:subtitle>
	<content:encoded><![CDATA[Sharon Arnold, a seasoned clinical operations executive with more than two decades of experience in both large pharma and emerging biotechs, speaks about how operational leadership determines whether innovation reaches the clinic successfully. ]]></content:encoded>
	<enclosure url="https://media.transistor.fm/6ccf40de/4cbf2435.mp3" length="44401508" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Sharon Arnold, a seasoned clinical operations executive with more than two decades of experience in both large pharma and emerging biotechs, speaks about how operational leadership determines whether innovation reaches the clinic successfully. ]]></itunes:summary>
	<itunes:image href="https://ssistrategy.com/wp-content/uploads/2025/11/clinical-operations-in-biotech-strategy.jpg"></itunes:image>
	<ssp:image>
		<ssp:url>https://ssistrategy.com/wp-content/uploads/2025/11/clinical-operations-in-biotech-strategy.jpg</ssp:url>
		<ssp:title>How Clinical Operations Shapes Biotech Strategy</ssp:title>
	</ssp:image>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>00:46:08</itunes:duration>
	<itunes:author><![CDATA[SSI Strategy]]></itunes:author>	<googleplay:description><![CDATA[Sharon Arnold, a seasoned clinical operations executive with more than two decades of experience in both large pharma and emerging biotechs, speaks about how operational leadership determines whether innovation reaches the clinic successfully. ]]></googleplay:description>
	<googleplay:image href="https://ssistrategy.com/wp-content/uploads/2025/11/clinical-operations-in-biotech-strategy.jpg"></googleplay:image>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>50 Episodes in: Lessons from The Emerging Biotech Leader</title>
	<link>https://ssistrategy.com/podcast/50-episodes-in-lessons-from-the-emerging-biotech-leader/</link>
	<pubDate>Mon, 10 Nov 2025 16:24:19 +0000</pubDate>
	<dc:creator><![CDATA[SSI Strategy]]></dc:creator>
	<guid isPermaLink="false">1ad0b30a-5134-5fcc-91ba-300cbef5b942</guid>
	<description><![CDATA[Podcast hosts, Kim Kushner and Ramin Farhood celebrate the anniversary of The Emerging Biotech Leader, marking three years, 50 episodes, and listeners across 50 countries.]]></description>
	<itunes:subtitle><![CDATA[Podcast hosts, Kim Kushner and Ramin Farhood celebrate the anniversary of The Emerging Biotech Leader, marking three years, 50 episodes, and listeners across 50 countries.]]></itunes:subtitle>
	<content:encoded><![CDATA[Podcast hosts, Kim Kushner and Ramin Farhood celebrate the anniversary of The Emerging Biotech Leader, marking three years, 50 episodes, and listeners across 50 countries.]]></content:encoded>
	<enclosure url="https://media.transistor.fm/d65679d8/3b08bfad.mp3" length="35074867" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Podcast hosts, Kim Kushner and Ramin Farhood celebrate the anniversary of The Emerging Biotech Leader, marking three years, 50 episodes, and listeners across 50 countries.]]></itunes:summary>
	<itunes:image href="https://ssistrategy.com/wp-content/uploads/2025/11/50-episodes-in.jpg"></itunes:image>
	<ssp:image>
		<ssp:url>https://ssistrategy.com/wp-content/uploads/2025/11/50-episodes-in.jpg</ssp:url>
		<ssp:title>50 Episodes in: Lessons from The Emerging Biotech Leader</ssp:title>
	</ssp:image>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>00:36:28</itunes:duration>
	<itunes:author><![CDATA[SSI Strategy]]></itunes:author>	<googleplay:description><![CDATA[Podcast hosts, Kim Kushner and Ramin Farhood celebrate the anniversary of The Emerging Biotech Leader, marking three years, 50 episodes, and listeners across 50 countries.]]></googleplay:description>
	<googleplay:image href="https://ssistrategy.com/wp-content/uploads/2025/11/50-episodes-in.jpg"></googleplay:image>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>
	</channel>
</rss>
